Although the frequency of both occurring simultaneously in patients with lung cancer is very low, targeting both EGFR and NTRK fusions together may provide clinical benefits (21), making them a treatment option for patients who have developed resistance to EGFR-TKIs. This evidence concerns the gene EGFR and lung cancer.